Xilio Therapeutics

United States
Waltham, Massachusetts, United States, 02451

Company profile

Xilio Therapeutics company profile

Xilio Therapeutics is a biotechnology company. They offer cancer immunotherapies designed to improve patient outcomes by unleashing the power of the immune system selectively at the site of the tumor. Their tumor-selective immunotherapies are based on its proprietary technology, which maximizes the potency of proven immuno-oncology therapies and restricts their activity to the tumor to minimize peripheral side effects.

Business identity

Phone number
+1 617 430 4680
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
2016-01-01, Year

Headquarters

Postal code
02451
Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
IPO
Funding rounds
7
Total equity funding
$330.1M
Last funding
Post IPO Equity / $35.8M / 2025-12-31
Last equity funding
Post IPO Equity / $35.8M
Investors
17
Lead investors
4
Founders
2
Articles
145
Exited on
2021-10-22

Founders and investors

Founders

John C. WilliamsUli Rodeck

Lead investors

Atlas VentureF-PrimeRock Springs CapitalTakeda Ventures

Investors

Bain Capital Life SciencesF-PrimeFrazier Life SciencesRA Capital ManagementSV Health Investors